These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 14640701)

  • 1. Degradation of beta-amyloid by proteolytic antibody light chains.
    Rangan SK; Liu R; Brune D; Planque S; Paul S; Sierks MR
    Biochemistry; 2003 Dec; 42(48):14328-34. PubMed ID: 14640701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity.
    Liu R; McAllister C; Lyubchenko Y; Sierks MR
    Biochemistry; 2004 Aug; 43(31):9999-10007. PubMed ID: 15287727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments.
    Kasturirangan S; Brune D; Sierks M
    Biotechnol Prog; 2009; 25(4):1054-63. PubMed ID: 19572401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway.
    Hook VY; Reisine TD
    J Neurosci Res; 2003 Nov; 74(3):393-405. PubMed ID: 14598316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity.
    Kasturirangan S; Boddapati S; Sierks MR
    Biochemistry; 2010 Jun; 49(21):4501-8. PubMed ID: 20429609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response to fibrillar beta-amyloid peptide.
    Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
    Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.
    Vingtdeux V; Hamdane M; Gompel M; Bégard S; Drobecq H; Ghestem A; Grosjean ME; Kostanjevecki V; Grognet P; Vanmechelen E; Buée L; Delacourte A; Sergeant N
    Neurobiol Dis; 2005 Nov; 20(2):625-37. PubMed ID: 15936948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of beta-secretase-like activity using a mass spectrometry-based assay system.
    Grüninger-Leitch F; Berndt P; Langen H; Nelboeck P; Döbeli H
    Nat Biotechnol; 2000 Jan; 18(1):66-70. PubMed ID: 10625394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
    Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
    Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
    Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
    J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.
    McCarty MF
    Med Hypotheses; 2006; 67(4):682-97. PubMed ID: 16828233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production.
    Zhou S; Zhou H; Walian PJ; Jap BK
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7499-504. PubMed ID: 15890777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42.
    Funamoto S; Morishima-Kawashima M; Tanimura Y; Hirotani N; Saido TC; Ihara Y
    Biochemistry; 2004 Oct; 43(42):13532-40. PubMed ID: 15491160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease.
    Johnston JA; Liu WW; Todd SA; Coulson DT; Murphy S; Irvine GB; Passmore AP
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1096-100. PubMed ID: 16246054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
    Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
    Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.